Literature DB >> 1678252

Expression of mdr-1/P-glycoprotein in human neuroblastoma.

S E Bates1, C Y Shieh, M Tsokos.   

Abstract

Increased expression of the mdr-1 gene encoding the drug efflux pump P-glycoprotein is a well-established mediator of acquired drug resistance in vitro, and a similar role has been hypothesized in vivo in human malignancy. Because expression of mdr-1 is increased in neuroblastoma cell lines by differentiating agents, the authors hypothesized a similar correlation with differentiation in vivo in neuroblastomas. In 12 tumors from 11 patients, total RNA analysis demonstrated no correlation with differentiation, but a correlation could be detected in the cell-based methods of analysis. The very primitive 'stroma'-poor, poorly differentiated neuroblastomas had low levels of mdr-1/P-glycoprotein. The intermediate grades had higher levels of expression and although heterogeneity of differentiation appeared within these tumors, both primitive and more differentiated cells expressed the gene at comparable levels within the tumor. One very well-differentiated neuroblastoma, a ganglioneuroma, had no detectable expression in the neurofibrillary material, but demonstrated expression in adjacent large ganglionic cells. Thus mdr-1/P-glycoprotein expression increased with increasing differentiation among tumors, and was present in ganglionic cells in the most well-differentiated tumor. The three tumors with the highest levels of expression were obtained from patients who received preoperative chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1678252      PMCID: PMC1886082     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  36 in total

1.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.

Authors:  R L Juliano; V Ling
Journal:  Biochim Biophys Acta       Date:  1976-11-11

2.  Evidence for reverse transformation in multidrug-resistant human neuroblastoma cells.

Authors:  M B Meyers; J L Biedler
Journal:  Prog Clin Biol Res       Date:  1988

3.  Morphology and growth, tumorigenicity, and cytogenetics of human neuroblastoma cells in continuous culture.

Authors:  J L Biedler; L Helson; B A Spengler
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

4.  Reduced permeability in CHO cells as a mechanism of resistance to colchicine.

Authors:  V Ling; L H Thompson
Journal:  J Cell Physiol       Date:  1974-02       Impact factor: 6.384

5.  Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies.

Authors:  J L Biedler; H Riehm
Journal:  Cancer Res       Date:  1970-04       Impact factor: 12.701

6.  Altered surface membrane glycoproteins in Vinca alkaloid-resistant human leukemic lymphoblasts.

Authors:  W T Beck; T J Mueller; L R Tanzer
Journal:  Cancer Res       Date:  1979-06       Impact factor: 12.701

7.  Different regulation of N- and c-myc expression during phorbol ester-induced maturation of human SH-SY5Y neuroblastoma cells.

Authors:  U Hammerling; C Bjelfman; S Påhlman
Journal:  Oncogene       Date:  1987       Impact factor: 9.867

8.  Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability.

Authors:  J R Riordan; V Ling
Journal:  J Biol Chem       Date:  1979-12-25       Impact factor: 5.157

9.  Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.

Authors:  E A Shafford; D W Rogers; J Pritchard
Journal:  J Clin Oncol       Date:  1984-07       Impact factor: 44.544

10.  Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience.

Authors:  E M Rosen; J R Cassady; C N Frantz; C Kretschmar; R Levey; S E Sallan
Journal:  J Clin Oncol       Date:  1984-07       Impact factor: 44.544

View more
  10 in total

Review 1.  Multidrug resistance in pediatric oncology.

Authors:  J F Kuttesch
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

Review 2.  The biology of the P-glycoproteins.

Authors:  C R Leveille-Webster; I M Arias
Journal:  J Membr Biol       Date:  1995-01       Impact factor: 1.843

Review 3.  Neuroblastoma: current drug therapy recommendations as part of the total treatment approach.

Authors:  F Berthold; B Hero
Journal:  Drugs       Date:  2000-06       Impact factor: 9.546

4.  Expression of MDR1/p-glycoprotein and multidrug resistance-associated protein in childhood solid tumours.

Authors:  Y Oda; I Röse; K Radig; W Wagemann; U Mittler; A Roessner
Journal:  Virchows Arch       Date:  1997-02       Impact factor: 4.064

Review 5.  Multidrug resistance in cancer chemotherapy.

Authors:  N H Patel; M L Rothenberg
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

6.  DNA and histone deacetylases as targets for neuroblastoma treatment.

Authors:  Marie Stiborová; Jitka Poljaková; Tomáš Eckschlager; Rene Kizek; Eva Frei
Journal:  Interdiscip Toxicol       Date:  2010-06

7.  Prognostic implication of immunodetection of P glycoprotein in Ewing's sarcoma.

Authors:  A Roessner; Y Ueda; B Bockhorn-Dworniczak; S Blasius; A Peters; P Wuisman; J Ritter; M Paulussen; H Jürgens; W Böcker
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer.

Authors:  S E Bates; B Meadows; B R Goldspiel; A Denicoff; T B Le; E Tucker; S M Steinberg; L J Elwood
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Combined Cytotoxicity of the Phycotoxin Okadaic Acid and Mycotoxins on Intestinal and Neuroblastoma Human Cell Models.

Authors:  Aiko Hayashi; Juan José Dorantes-Aranda; John P Bowman; Gustaaf Hallegraeff
Journal:  Toxins (Basel)       Date:  2018-12-08       Impact factor: 4.546

10.  Expression of MDR1/P glycoprotein in human sarcomas.

Authors:  B Vergier; L Cany; F Bonnet; J Robert; A de Mascarel; J M Coindre
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.